The Release of the Bromodomain Ligand N,N- Dimethylacetamide Adds Bioactivity to a Resorbable Guided Bone Regeneration Membrane in a Rabbit Calvarial Defect Model

Barbara Siegenthaler; Chafik Ghayor; Nisarat Ruangsawasdi; Franz E Weber

doi:10.3390/ma13030501

The Release of the Bromodomain Ligand N,N- Dimethylacetamide Adds Bioactivity to a Resorbable Guided Bone Regeneration Membrane in a Rabbit Calvarial Defect Model

Materials (Basel). 2020 Jan 21;13(3):501. doi: 10.3390/ma13030501.

Authors

Barbara Siegenthaler¹, Chafik Ghayor¹, Nisarat Ruangsawasdi², Franz E Weber^{1

3

4}

Affiliations

¹ Oral Biotechnology & Bioengineering, Center for Dental Medicine/MKG, University of Zürich, 8032 Zurich, Switzerland.
² Department of Pharmacology, Faculty of Dentistry, Mahidol University, 10400 Bangkok, Thailand.
³ Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, 8057 Zurich, Switzerland.
⁴ CABMM Center for Applied Biotechnology and Molecular Medicine, University of Zurich, 8057 Zurich, Switzerland.

Abstract

N,N-Dimethylacetamide (DMA) is FDA approved as an excipient and is used as drug-delivery vehicle. Due to its amphipathic nature and diverse bioactivities, it appears to be a good combination of biodegradable poly-lactide-co-glycolide (PLGA)-based guided bone regeneration membranes. Here we show that the solvent DMA can be loaded to PLGA membranes by different regimes, leading to distinct release profiles, and enhancing the bone regeneration in vivo. Our results highlight the potential therapeutic benefits of DMA in guided bone regeneration procedures, in combination with biodegradable PLGA membranes.

Keywords: DMA; GBR; N,N-Dimethylacetamide; bioactive membrane; guided bone regeneration.

Grants and funding

31003A 140868/Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung